The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...
The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
1 “TAR-200 represents a novel interventional approach for the treatment of localized bladder cancer where today, unfortunately, options are limited and include antiquated BCG therapy or radical ...
Pfizer Inc. announced positive topline results from its pivotal phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette ...
(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...
ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...
"In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025.
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC Completed approximately $100 million public offering, extending runway into 2027 Initial data from 12-month ev ...